# A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)

> **NCT01730482** · PHASE1 · COMPLETED · sponsor: **Amicus Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** [14C] AT1001

## Key facts

- **NCT ID:** NCT01730482
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01730482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01730482, "A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01730482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*